Timothy Edward Lee Sells 18,425 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 18,425 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total value of $15,477.00. Following the completion of the transaction, the insider owned 178,937 shares in the company, valued at approximately $150,307.08. The trade was a 9.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

• On Monday, August 17th, Timothy Edward Lee sold 22,355 shares of Invivyd stock. The shares were sold at an average price of $0.72, for a total value of $16,095.60.

Invivyd Stock Performance

Shares of NASDAQ IVVD traded up $0.13 during midday trading on Tuesday, hitting $0.87. 7,732,095 shares of the stock traded hands, compared to its average volume of 3,061,089. Invivyd, Inc. has a one year low of $0.48 and a one year high of $3.07. The business has a 50 day moving average price of $0.77 and a two-hundred day moving average price of $1.23. The company has a market cap of $255.75 million, a PE ratio of -2.63 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The firm had revenue of $14.29 million during the quarter, compared to the consensus estimate of $14.40 million. As a group, equities research analysts forecast that Invivyd, Inc. will post -0.52 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on IVVD shares. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.00.

Hedge Funds Weigh In On Invivyd

Several hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its stake in shares of Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after buying an additional 71,485 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after acquiring an additional 391,617 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Invivyd during the second quarter valued at approximately $158,000. Jane Street Group LLC purchased a new stake in shares of Invivyd during the second quarter valued at approximately $147,000. Finally, Vanguard Group Inc. lifted its holdings in Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after acquiring an additional 1,834,970 shares during the period. Institutional investors own 70.36% of the company’s stock.

Trending Headlines about Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.